Effect of Autologous or Allogeneic Anti-CD3 Monoclonal Antibody Activated Killer Cells on Normal Hematopoietic Cells
- Author:
Bao-An CHEN
1
,
2
;
Su-Ning CHEN
;
Cui-Ping LI
;
Sheng XIA
;
Bao-Cui JIN
;
Jun WANG
;
Ze-Ye SHAO
;
Chong GAO
;
Jia-Hua DING
;
Yun-Yu SUN
Author Information
1. Department of Hematology, School of Clinical Medicine/Zhong-Da Hospital, Southeast University, Nanjing 210009, China
2. Nanjing Red Cross Blood Center, Nanjing 210009, China.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2001;9(4):338-342
- CountryChina
- Language:Chinese
-
Abstract:
In order to investigate the effect of autologous and allogeneic anti-CD3 McAb activated killer cells (CD3AK) on normal hematopoietic cells, the immobilized anti-CD3 McAb and low concentration IL-2 were used to activate CD3AK. Flow cytometry was used to assay the phenotype change of CD3AK to analyze the proportional change of CD34(+) cells in normal bone marrow mononuclear cells (BMMNC) cocultured with autologous or allogeneic CD3AK. The effect of CD3AK on normal hematopoietic progenitor cells was also assayed by methylcellulose clonogenic culture of CFU-GM. It was found that 3 - 5 micro g/ml immobilized anti-CD3 McAb and 100 U/ml IL-2 could activate CD3AK effectively. There were 99.51% CD3(+) cells in CD3AK groups. When BMMNCs from healthy volunteers were cocultured with allogeneic CD3AK for six hours, the percentage of CD34(+) cells was decreased 32.37%. CD3AK had no significant influence on autologous BMMNC. Allogeneic and autologous CD3AK were cultured with BMMNC from healthy volunteers for six hours, and then CFU-GM was evaluated. Allogeneic CD3AK inhibited 20.44% CFU-GM formation, but autologous CD3AK had no inhibition on CFU-GM. It is concluded that CD3AK has no inhibition to autologous normal hematopoietic progenitor cells after cocultured with them from these results, while allogeneic CD3AK inhibits the normal hematopoietic progenitor cells significantly.
